Adlai Nortye Ltd
ANL1.480USD
+0.030+2.07%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
163.84MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Adlai Nortye Ltd Unternehmen
Adlai Nortye Ltd is a Cayman Island-based clinical-stage biotechnology company. The Company is engaged in the discovery and development of cancer therapies. The Company’s pipeline includes three clinical-stage drug candidates, buparlisib (AN2025), palupiprant (AN0025), and AN4005, as well as three preclinical candidates. AN2025 is a pan-phosphoinositide 3-kinase (PI3K) inhibitor that is designed to act against solid tumors. AN2025 is undergoing Phase III, open-label clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas (HNSCC) after anti-programmed death-1 (PD-1) or its ligand (PD-L1) treatment. AN0025 is a small molecule prostaglandin E receptor 4 (EP4) antagonist. AN4005 is an internally discovered oral small molecule PD-L1 inhibitor in development to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include: AN8025, AN1025, and AN9025.
Unternehmensinformationen
BörsenkürzelANL
Name des UnternehmensAdlai Nortye Ltd
IPO-datumSep 29, 2023
CEOMr. Lars Erik Birgerson
Anzahl der mitarbeiter123
WertpapierartDepository Receipt
GeschäftsjahresendeSep 29
Addressec/o PO Box 309
StadtGRAND CAYMAN
BörseNASDAQ Global Market Consolidated
LandCayman Islands
PostleitzahlKY1-1104
Telefon18482307430
Websitehttps://www.adlainortye.com/
BörsenkürzelANL
IPO-datumSep 29, 2023
CEOMr. Lars Erik Birgerson
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Ping Ji
Ms. Ping Ji
Director Nominee
Director Nominee
--
--
Mr. Yang Lu
Mr. Yang Lu
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Victoria Elizabeth Demby
Dr. Victoria Elizabeth Demby
Senior Vice President, Global Head of Regulatory Affairs
Senior Vice President, Global Head of Regulatory Affairs
--
--
Ms. Wei (Vicky) Zhang
Ms. Wei (Vicky) Zhang
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Cheguo Cai
Mr. Cheguo Cai
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Lars Erik Birgerson
Mr. Lars Erik Birgerson
President, Director Nominee, Chief Medical Officer, Chief Executive Officer of U.S. Subsidiary
President, Director Nominee, Chief Medical Officer, Chief Executive Officer of U.S. Subsidiary
--
--
Mr. Ming Lun (Alan) Tse
Mr. Ming Lun (Alan) Tse
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Shaorong Liu
Mr. Shaorong Liu
Independent Director Nominee
Independent Director Nominee
--
--
Dr. Kaiyang Tang
Dr. Kaiyang Tang
Senior Vice President, Global Head of Clinical Operations
Senior Vice President, Global Head of Clinical Operations
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Ping Ji
Ms. Ping Ji
Director Nominee
Director Nominee
--
--
Mr. Yang Lu
Mr. Yang Lu
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Victoria Elizabeth Demby
Dr. Victoria Elizabeth Demby
Senior Vice President, Global Head of Regulatory Affairs
Senior Vice President, Global Head of Regulatory Affairs
--
--
Ms. Wei (Vicky) Zhang
Ms. Wei (Vicky) Zhang
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Cheguo Cai
Mr. Cheguo Cai
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Lars Erik Birgerson
Mr. Lars Erik Birgerson
President, Director Nominee, Chief Medical Officer, Chief Executive Officer of U.S. Subsidiary
President, Director Nominee, Chief Medical Officer, Chief Executive Officer of U.S. Subsidiary
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, May 24
Aktualisiert: Sat, May 24
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Nortye International Ltd
7.47%
Nortye Talent Ltd
1.12%
Cantor Fitzgerald, L.P
0.13%
Millennium Management LLC
0.04%
UBS Financial Services, Inc.
0.01%
Other
91.23%
Aktionäre
Aktionäre
Anteil
Nortye International Ltd
7.47%
Nortye Talent Ltd
1.12%
Cantor Fitzgerald, L.P
0.13%
Millennium Management LLC
0.04%
UBS Financial Services, Inc.
0.01%
Other
91.23%
Aktionärstypen
Aktionäre
Anteil
Corporation
14.25%
Investment Advisor
0.14%
Hedge Fund
0.04%
Other
85.57%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
8
4.51M
14.43%
+4.45M
2025Q1
8
4.51M
14.43%
+4.45M
2024Q4
5
2.23M
7.14%
+2.17M
2024Q3
5
2.24M
7.16%
+2.18M
2024Q2
5
2.23M
7.15%
+2.17M
2024Q1
5
2.23M
7.15%
+2.17M
2023Q4
5
2.24M
7.16%
+2.19M
2023Q3
3
48.25K
0.15%
+48.25K
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Nortye International Ltd
2.33M
7.47%
+2.33M
--
Dec 31, 2024
Nortye Talent Ltd
349.27K
1.12%
+349.27K
--
Dec 31, 2024
Cantor Fitzgerald, L.P
40.31K
0.13%
--
--
Mar 31, 2025
Millennium Management LLC
11.56K
0.04%
-5.03K
-30.31%
Mar 31, 2025
UBS Financial Services, Inc.
4.67K
0.01%
+4.67K
+467400.00%
Mar 31, 2025
Morgan Stanley & Co. LLC
19.00
0%
+19.00
--
Mar 31, 2025
Qube Research & Technologies Ltd
--
0%
-88.00
-100.00%
Sep 30, 2024
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
